key: cord-0997956-dltwj6rj
authors: Komenda, Paul VJ.; Harper, Gerard; Wilson, Lucy M.; Mitra, Sandip; Breen, Cormac; Milad, John E.
title: Hemodialysis With the Quanta SC+: Efficacy and Safety of a Self-care Hemodialysis Machine
date: 2020-10-21
journal: Kidney Med
DOI: 10.1016/j.xkme.2020.07.007
sha: 357b5fa43b33dd016c411ad6be4f9f054dbca936
doc_id: 997956
cord_uid: dltwj6rj

RATIONALE & OBJECTIVE: Most kidney failure patients receive hemodialysis three times-per-week in a facility. More frequent and longer-duration dialysis prescriptions improve a number of key outcome measures. These prescriptions are best suited to self-care and home regimens. The Quanta SC+ hemodialysis system is a novel device with demonstrated ease of use for patients and healthcare practitioners through Human Factors Testing. The primary objective of this study is to report the efficacy and safety of the SC+ system using conventional hemodialysis prescriptions. STUDY DESIGN: Non-randomized, observational study SETTING: & Participants: Prevalent hemodialysis patients in 4 sites in the United Kingdom were recruited to switch from their current device to the SC+ system with no other changes to their prescription. INTERVENTIONS: SC+ hemodialysis system OUTCOMES: Efficacy data were collected in terms of dialysis adequacy, urea reduction ratios, and net fluid removal accuracy. RESULTS: 60 patients were enrolled in the study resulting in 1,333 evaluable treatments. The threshold spKt/V of 1.2 was exceeded in 96.6 percent of treatments in patients receiving three-times weekly regimens, while the threshold stdKt/V of 2.1 was exceeded in 94% of treatments and 97.6% of treatments in patients without significant residual kidney function. Ultrafiltration accuracy was determined by measuring net fluid removal and validated to be within acceptable limits. The adverse event profile during treatment was typical of hemodialysis. There were no serious adverse events. LIMITATIONS: Few patients on high-frequency treatment regimens were enrolled. CONCLUSIONS: The SC+ system delivers safe and effective hemodialysis across a range of patients and dialysis prescriptions. It is one of the smallest systems available and has validated usability for patients to perform self-care safely with minimal training. This device may encourage patients to feel empowered to take on home hemodialysis, unlocking beneficial clinical and patient-reported outcome associated with these modalities.

The prevalence of kidney failure is rising globally with an estimate of over 4.1 million individuals affected. 1 While the preferred treatment for kidney failure is transplantation, most patients are treated with facility-based hemodialysis, administered by specialized health care practitioners three times per week. Facility-based hemodialysis has been the dominant mode of dialysis delivery in the developed world for over 30 years, with small incremental improvements in the technology of devices over this time.

Health outcomes for patients receiving three times per week, conventional hemodialysis prescriptions are unacceptable, with a one-year mortality of 20 percent and a five-year mortality of 50 percent. 2 Patients are known to suffer from poor health-related quality of life and patient advocates have identified key priorities for innovation in improving patient-reported outcome measures including improved treatment options for patients on dialysis. 3, 4 In addition, three times per week, facility-based hemodialysis is consistently identified as one of the most costly options for treating kidney failure across multiple health care systems, driven primarily by the need to build and maintain expensive capital infrastructure and highly-skilled human resources to sustain patients. 5 It has been well established that many patients are able to administer their own dialysis safely in their home or in a clinic setting. More frequent and longer hemodialysis prescriptions have been demonstrated to improve important cardiovascular endpoints in randomized control trials and large observational studies. 2 The Advancing American Kidney Health initiative recognizes the growing number of individuals advancing to kidney failure and called for 80% of new patients to receive care through home dialysis or kidney transplant. 6 The Covid-19 pandemic has also exposed transmission risks J o u r n a l P r e -p r o o f inherent to center-based hemodialysis that would be substantially mitigated by transition of a greater proportion of in-centre patients home modalities. 7 While there has been some improvement in the technology to provide user-friendly patient-oriented hemodialysis devices over the past few years, there are limited choices in the market for devices that can be used for home or self-care. Currently, few devices exist that have undergone thorough human factor testing and have been designed in collaboration with patients for self-care.

Quanta Dialysis Technologies (Alcester, UK) has developed SC+, a compact personal hemodialysis system designed and validated as easy to use by patients with a low user error rate after minimal training. 8 A key purported differentiator of the Quanta SC+ hemodialysis system is its ability to be used across a continuum of hemodialysis prescriptions -from conventional three times per week, as typically experienced by most patients globally, to the clinically-preferred frequent and long prescriptions. The primary objective of this study was to demonstrate the safety and efficacy of the SC+ system in a clinical setting using conventional thrice-weekly hemodialysis prescriptions.

A prospective, observational study design was used to assess the dialysis efficacy and safety of the SC+ hemodialysis system. Treatments were conducted in four hemodialysis facilities within the United Kingdom. The SC+ system received its CE mark in 2015. The system is designed to treat patients with kidney failure with or without ultrafiltration (UF), and can be used for hemodialysis in both home and clinic environments. The system is indicated for use by patients greater than 40 kg who have a J o u r n a l P r e -p r o o f typical vascular access site such as an arteriovenous fistula, graft or a central venous catheter.

Prevalent hemodialysis patients within selected sites were recruited to dialyze using the SC+ device with no substantive changes in their typical dialysis prescription in terms of duration, frequency, dialysate composition, or dialyzer. Individuals over 18 years of age were considered for a trial of the SC+ device provided they were over 40 kg, able to speak English and provide informed consent, had a stable, well-functioning, permanent vascular access, had no transplant or modality switches planned within 12 months, and had no comorbidities which, in the opinion of their consultant nephrologist, would preclude successful participation in the study. These comorbidities included unstable cardiac disease or blood pressure, advanced malignancies, or other conditions or frailty that may influence mortality within a 12-month period. Patients were excluded from the study if they had demonstrated non-adherence with attending treatments, dietary and/or fluid restrictions within the previous three months, current or planned hospitalization or major surgery, planned or active pregnancy, had off-label prescriptions, or were using a hemodialysis device outside the scope of the CE mark and intended instructions for use of the SC+.

Patients who met the selection criteria provided informed consent for a change in their hemodialysis device and to have their usual clinical data recorded for evaluation and reporting purposes. Research ethics board review was waived as per NHS guidance as no randomization, off-label use, or generalizability claims were to be made outside of the domain of this study. 9

J o u r n a l P r e -p r o o f Baseline demographic and comorbidity characteristics of the patients recruited were collected including age, sex, type of vascular access, cause of kidney failure, dialysis vintage, and the presence of diabetes, cardiovascular disease, peripheral arterial disease, hypertension, cerebrovascular accident, bleeding disorders, malignancy liver failure, and a host of other less common comorbid conditions. A detailed medication history was taken at baseline for each patient. The study's primary endpoint was to measure device performance of the SC+. System performance was measured by a composite of dialysis adequacy as measured by a delivered single pool Kt/V (spKt/V) > 1.2 as per KDOQI guidelines, weekly standard Kt/V (StdKt/V), and net fluid removal (NFR) accuracy. [10] [11] [12] At each dialysis run, typical dialysis parameters were collected at the point-ofcare including venous and arterial pressures, blood pressures throughout treatment, preand post-treatment weight, and estimates of mass of fluid and food intake during treatment. Actual ultrafiltration (UF) achieved was calculated from pre-and posttreatment weights and adjusted for fluid and dietary intake during treatment as well as any other salient intra-dialytic events such as vomiting or toilet visits. Patient blood work was taken as per each facility's usual protocol and dialysis adequacy was measured using spKt/V and StdKt/V calculations. [12] [13] [14] Data were captured at the point-of-care using data collection worksheets during treatments at the outset of the study. No unique patient identifiers were collected on the data capture worksheets aside from a patient ID number. The worksheets were completed by the Quanta clinical team and retained for subsequent electronic data entry. These paper records formed the study's source data and were subsequently used for source data J o u r n a l P r e -p r o o f verification and database validation audits. In addition, during source data verification these records were cross-referenced with electronic "data logger" files collected during treatments by the machine if required. An internal system, referred to as the "Pilot Diary", and subsequently a commercial clinical trial database system SMART-TRIAL (MEDEI ApS, Aalborg Øst, Denmark), comprised the databases used to enter, retain, and report the clinical data collected for this study. Quality control checks included preprogrammed audits in SMART-TRIAL and manual data review. Data were exported from the electronic data capture systems into Microsoft Excel for analysis. The database was formally audited periodically to identify potential discrepancies. Entries relating to these discrepancies were subsequently verified against source data and the database was updated where required. Systematic adjustment took place when dialysis treatments were at least 15 minutes shorter than the targeted time. In these cases, the target UF weight was adjusted according to the percentage completed of the target treatment time. This reflects the linear nature of fluid removal over the course of the treatment and allows a revised, more accurate, target to be calculated for comparison with the patient weight loss over the treatment and thereby a more meaningful assessment of NFR. In some cases, UF was paused or adjusted during treatment. UF target was adjusted in cases where actual amount of fluid removed was materially lower than target UF. In these cases, total UF time and rate were determined by reference to the data logger record (coming off the device), where available.

Peri-procedural adverse event data were collected as part of the study. Events were reviewed to ascertain causality. Device-related Adverse Events causing harm or potential harm would, per protocol, constitute a failure to meet the primary safety J o u r n a l P r e -p r o o f endpoint. Examples of these events include Serious Adverse Device Effects and Adverse Device Effects with serious potential. Events categorized as an adverse device effect are considered related to SC+ and/or proprietary consumables. All other events are considered unrelated to the system and have been assessed for trends compared with conventional hemodialysis therapy. Adverse events that could potentially be considered serious were reviewed by Quanta's Medical Advisory Board in order to adjudicate whether they should be considered to be serious and/or device-related.

Expected procedural adverse events common during hemodialysis treatmentsincluding, but not limited to, hypotension, dizziness, cramping, nausea and vomitingwere also captured during procedures.

Summary statistics (mean, sample size, SD, minimum maximum, median 25 th and 75 th percentiles) were computed to characterize patient background parameters and to determine the effectiveness of treatment with respect to urea clearance and ultrafiltration.

Clearance was calculated from pre-and post-treatment blood urea nitrogen values and expressed as URR, spKt/V and stdKt/v. Mean ± standard deviation or median with 25 th and 75 th percentiles are presented, as appropriate. The Pearson correlation coefficient, fit line and intercept were calculated for the measured weight loss and target weight loss data sets.

From June 2015 to January 2018, a total of 1,333 hemodialysis treatments were successfully conducted in 60 patients who completed at least 3 treatments using the SC+ 

Pre-and post-treament blood urea nitrogen valuse were available for 134 treatments according to centre protocols (monthly blood analyses). The median spKt/V that was delivered for treatments in patients receiving three times weekly regimens was 1.73 (25 th and 75 th percentiles 1.50 and 1.89, respectively) ( Figure 1 ). The threshold spKt/V of 1.2 was exceeded in 96.6 percent of treatments in patients receiving threetimes weekly regimens. Treatments in patients receiving three treatments per week falling below the guideline threshold all occurred in patients with significant residual kidney function with the exception of one patient who had been very unwell in the days prior to treatment resulting in severely diminished food intake, and a correspondingly low pretreatment urea concentration. Table 2 shows values for spKt/V across a range of dialysis prescriptions in terms of time and frequency in patients with and without significant residual kidney function.

The median stdKt/V that was delivered was 2.46 (25 th and 75 th percentiles 2.27 and 2.56, respectively). The threshold stdKt/V of 2.1 was exceeded in 94.0% of treatments. When patients with significant residual kidney function were excluded 97.6% of treatments exceeded the threshold of 2.1. Two treatments that did not meet the threshold stdKt/V threshold were marginally below (2.03 and 2.07) while the other was the patient who had been unwell, as described in the previous paragraph.

The median urea reduction ratio (URR) achieved was 76.1% (25 th and 75 th percentiles 70.6% and 79.7%, respectively), with patients undergoing a standard threetimes per week dialysis prescription having a median URR of 77.2%. The mean URR for all treatments in qualified patients was 74.3% (n=134) with a standard deviation of 7.4%.

These figures are well above the 65% that has been proposed as a threshold for 3-times weekly dialysis in patients without residual kidney function in the NKF-KDOQI guidelines. 10 Figure 2 shows the percentage of URR values falling within specific 5% bounds for patients on a three times per week regimen. Only one value was markedly below the threshold of 65%. This was the same patient who presented below the threshold spKt/V due to being unwell prior to treatment. They also presented with a low pre-treatment blood urea nitrogen. Two of the other values not reaching the threshold were in patients with RRF while the remaining value was only marginally below, at 64%.

Overall, mean UF target matched with mean NFR achieved, with parameters averaging 2.20 ± 0.95 kg and 2.26 ± 0.97 kg, respectively. The fit line for the data is within the NFR error specified by International Standards for hemodialysis (100 mL/h or 400 mL/treatment over a 4h treatment) as shown in Figure 3 . 15 The correlation between J o u r n a l P r e -p r o o f programmed fluid removal (adjusted for shortened treatments) and recorded weight loss was strong (R 2 = 0.876). Median deviation (positive or negative) from idealized fluid removal was 0.06 kg/h (25 th and 75 th percentiles 0.03 and 0.09, respectively).

During this study, symptomatic events were captured irrespective of whether an intervention was made to resolve the event ( Table 3 ). All reported Adverse Event observations were related to minor complications that are common in hemodialysis (Table 4 -5). The most frequent of these was hypotension, which was observed in 13% of all reported treatments. This is well within the normal range as previously documented.

Frequency of other reported events is also in keeping with that expected for patients undergoing hemodialysis.

One adverse device effect without serious potential was reported. This comprised a system failure prior to the end of treatment. Blood was not returned to patient as per unit protocol and one circuit of blood was lost. No symptoms or adverse events were reported in association with this event. Root cause analysis revealed a loose blood pump controller cable. The safety systems integrated into SC+ correctly prevented dialysis from continuing.

The results of this study demonstrate that SC+ is a safe and effective hemodialysis system when using a range of conventional dialysis prescriptions in a population broadly reflective of a typical hemodialysis population. We report the results of 1,333 hemodialysis treatments performed in 60 prevalent hemodialysis patients who largely principles of the SC+ system in terms of patient usability with minimal training. 8 For this reason, the SC+ system is a well-suited hemodialysis device for patient use across a wide range of dialysis prescriptions in the home and in facilities. The device requires reverseosmosis quality water and can be simply installed into the ring main of a dialysis clinic or with a single-station reverse-osmosis unit. Quanta has developed a water solution that contains an reverse-osmosis unit and all standard pre-filtration requirements that has a similar 'footprint' to SC+. This simplifies the installation of the SC+ system requiring only a dedicated electrical circuit, water outlet and drain tube in a home setting. This cart-J o u r n a l P r e -p r o o f based solution, upon which the SC+ can be placed, also enables easy redeployment should a patient change treatment modality, e.g. receiving a transplant. The commercial system also includes a suite of digital health tools that automatically and securely transfer treatment data to the clinic as well as providing information on the performance of the machine enabling pre-emptive maintenance. This will support effective remote management of the patient.

Our study has several strengths. It selected four distinct dialysis programs with unique characteristics and patient care protocols, and had a patient population with significant age and weight ranges. The study had participants utilizing a range of dialysis prescriptions, varying in number of treatments per week and the type of treatment (nocturnal, short daily, conventional three times per week). Over a significant number of treatments there were no observed machine related adverse device events, and patient adverse events were at an acceptable level for a typical dialysis population receiving mainly conventional thrice-weekly dialysis.

This study has some weaknesses. A few patients fell below the standards for dialysis adequacy we try to achieve. The vast majority of patients that did fall below acceptable clearances were all explained by the presence of significant residual kidney function or transient illness, which is typical in a facility-based hemodialysis program.

Few patients were included in the study on treatment frequencies greater than 3 times weekly. The protocol specified that patients recruited should continue on their current prescription. The high proportion of patients on three-times weekly treatment regimens reflects the prevailing prescriptions in centre-based hemodialysis -the pool from which the majority of patients were recruited. Future studies will examine the performance of J o u r n a l P r e -p r o o f SC+ in patients prescribed higher-frequency regimens. Consistent historical data are not available for all patients so we cannot report on a comparison between SC+ and the prior machine.

Measured weight loss, as adjusted for fluid and food intake during treatment, is compared with the target ultrafiltration volume in order to determine the NFR error. In accordance with the relevant standards and our system specification, the acceptable limit of NFR error is +/-100 ml/h or 400 ml per 4hr treatment. SC+ has consistently demonstrated conformity with these limits when evaluated under appropriate, controlled laboratory settings, as reported in formal verification testing. While there is variability in the NFR error data obtained in treatments conducted with SC+, this appears to be related to 'real-world' variability (such as unanticipated intradialytic fluid and food intake during treatment or changes in clothing and personal items while being weighed) rather than the performance of SC+, and is consistent with usual clinical experience. Additionally, no treatments greater than 5 hours were tested in this study. The commercial version of the SC+ platform has a 300 ml/min dialysate flow rate setting in addition to the high-flow (500 ml/min) setting used in all treatments in this study. This enables treatments up to 8 hours in duration and will be tested in future studies of the platform. An infusion port is incorporated into the blood-line in order to accommodate the delivery of heparin. The lower flow setting could also be used to reduce overall water requirements compared with the high-flow setting in locations where water is scarce or expensive.

We did not perform a structured usability or human factors component to this study. However, it is reassuring that qualitative feedback on the device was generally positive and many patients expressed an interest in remaining on the device beyond the J o u r n a l P r e -p r o o f study period and some patients transitioned to self-care who were previously dependent on clinic staff.

After 30 years of minor incremental improvements to hemodialysis devices, it is encouraging that there are now some emerging options for patients wishing to try selfcare or home hemodialysis on a global scale. Exciting results in terms of usability, improved cardiovascular outcomes, and patient recovery have been published with the NxStage device. [16] [17] [18] [19] The Tablo device (Outset Medical) is an emerging device with similarly encouraging usability use that may encourage more patients to become empowered with self-care. 20 It is our hope that more choice in the market for both providers and patients will grow the use of self-care and more frequent home dialysis prescriptions, achieving better patient outcomes at lower cost to providers.

With this study, the SC+ hemodialysis system demonstrates key differentiating features from existing hemodialysis devices by delivering the power of large conventional devices in a patient-friendly form with demonstrated usability. SC+ is flexible across a variety of dialysis prescriptions including conventional, three times-perweek, short daily, and nocturnal dialysis. The system has also been validated on patients with a broad range of sizes and weights. The SC+ system could be greatly utilized in the Advancing American Kidney Health initiative for increased home dialysis in all new patients experiencing kidney failure. 6 It could also assist in transitioning many in-center patients to the home as a lower-risk environment in the context of the Covid-19 pandemic. It is our hope that this device empowers many more patients to engage with self-care dialysis and enjoy its improved clinical and patient-reported health outcomes while unlocking greater value for providers. n/a n/a 0 n/a n/a 0 7

3.5 1.2 1 3.5 1.2 1

The n value refers to number of data points derived from pre-and post-treatment blood urea nitrogen values taken monthly as part of standard of care 

Heparin (n=1; 2%) LMWH (n=47; 78%) Saline flush (n=1; 2%) None (n=11; 18%)

Vascular Access Brachial Fistula (n = 36; 60%) Brachial Graft (n = 3; 5%) Radial Fistula (n = 17; 28%) Radial Graft (n = 0; 0%) Femoral Graft

Dialyzer Size Range (number of treatments)

Fresenius FX-60 (n=213; 16%) Fresenius FX-80 (n=261; 20%) Fresenius FX-100 (n=374; 28%) Fresenius FX-120 (n=114; 9%) Gambro 170H (n=171; 13%) Gambro 210H (n=195; 15%) Nipro

The effects of frequent nocturnal home hemodialysis: The Frequent Hemodialysis Network Nocturnal Trial

A patient-centred approach to measuring quality in kidney care

Setting research priorities for patients on or nearing dialysis

Cost of dialysis therapy by modality in Manitoba

HHS Unveils Kidney Initiative with Bold Goals to Increase Home Dialysis, Transplants

Hemodialysis and COVID-19: an Achilles' heel in the pandemic health care response in the United States

Human factors testing of the Quanta SC+ hemodialysis system: An innovative system for home and clinic use

KDOQI Clinical Practice Guideline for Hemodialysis Adequacy

Theoretical basis for and improvement of Daugirdas' second generation formula for single-pool Kt/V

Second Generation Logarithmic Estimates of Single-Pool Variable Volume Kt/V: An Analysis of Error

Calculation of Standard Kt/V (stdKt/V) with Corrections for Postdialysis Urea Rebound

Preparation and quality management of fluids for haemodialysis and related therapies -Part 3: Water for haemodialysis and related therapiee

Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease

Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use

Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use

Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study

Results of human factors testing in a novel Hemodialysis system designed for ease of patient use